Section 4 Plastic and Reconstructive Problems

TR I NDADE DE ALME I DA ET AL

2–8 1 C 2–8 1 C 2–8 1 C 2–8 1 C o 25 1 C 2–8 1 C

500 m g/mL HSA

United States, some European coun- tries

sciences Inc./Eisai Co., Ltd.

NaCl 0.1M

Disodium succinate

0.01MHCl (to adjust pH)

Water for injection

Mode of action SNAP 25/SV2 SNAP 25/SV2 SNAP 25 SNAP 25 SNAP 25 Vesicle associated membrane protein U/vial 100 or 200 300 or 500 100 or 50 100 100 or 50 2,500, 5,000, or 10,000 Pharmaceutical form Powder dissolved in solution for injec- tion Powder dissolved in solution for injec- tion Powder dis- solved in solu- tion for injection Powder dis- solved in solution for injection Powder dissolved in solution for injec- tion Solution Excipients 500 m g HSA 125 m g HSA 500 m g HSA 1,000 m g HSA

Botulinum toxin type B (700 kDa)

Cervical dystonia

Meditoxin Botulift Xeomin, Bocoture Myobloc, Neurobloc

Solstice Neuro-

OnabotulinumtoxinA AbobotulinumtoxinA BONTA BONTA IncobotulinumtoxinA RimabotulinumtoxinB Company Allergan, Inc. Ipsen Inc./Medicis Inc. Lanzhou Medy-Tox Inc., South Korea Merz Pharmaceuti- cals Commercial names Botox, Botox cos metic, Vistabel, Vistabex Dysport, Reloxin, Azzalure Prosigne Lantox, Redux Neuronox, Approvals Worldwide, includ- ing United States and Canada In more than 65 countries, includ- ing United States and Canada 4 10 countries including China Korea, India, Latin South America Germany, other European coun- tries, Mexico, Argentina, Brazil strain) A A Type A-Hall strain B Active sub- stance Botulinum toxin type A complex (400 kDa) Botulinum toxin type A (900 kDa) y Botulinum toxin type A (940 kDa) Botulinum toxin type A, free from

complexing pro- teins (150 kDa)

cervical dystonia, cosmetic use in

some countries

4.7mg sucrose

0.9mg NaCl

Blepharospasm Blepharospasm,

Blepharospasm, cervical dysto- nia, glabellar

lines, hyper- hidrosis

25mg dextran

25mg sucrose

5mg gelatin

cervical dystonia, glabellar lines

2.5mg lactose

Blepharospasm,

Type Type A-Hall strain Type A (NCTC 2916 Botulinum toxin type A complex (900 kDa) Indications Blepharospasm, cervical dystonia, glabellar lines, hyperhidrosis, chronic migraine

0.9mg NaCl

Transportation and storage

before dilu- tion

TABLE 1. Botulinum Toxin Manufacturer Recommendations on Supply, Dilution, and Storage

3 7 : 1 1 : NOVEMBER 2 0 1 1